grant
BCC for Prostate Cancer: Discovery and Translation of Biomarkers for Clinical Unmet Needs
Organization JOHNS HOPKINS UNIVERSITYLocation BALTIMORE, UNITED STATESPosted 20 Jul 2023Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY2025Active Follow-upAddressAdoptionAngiopoietin 1 ReceptorAngiopoietin Receptor Tie-2AssayBioassayBiological AssayBiological MarkersBiopsyBlood SerumBody TissuesCD202B AntigenCLIA accreditedCLIA approvedCLIA certifiedCLIA compliantCLIA licensedCancer PatientCancer TreatmentCertificationClassificationClinicalClinical EvaluationClinical ResearchClinical StudyClinical TestingClinical TreatmentCommunitiesComputer ModelsComputerized ModelsDetectionDevelopmentDiagnosticDiseaseDisorderEDRNEarly Detection Research NetworkEndothelial TEK Tyrosine KinaseEnrollmentEpithelial-Specific Protein Receptor Tyrosine Kinase TIE-2FDA approvedGDF-1GDF15GDF15 geneGlycoproteinsGoalsHealthImmunoassayIndustryLaboratoriesLaser ElectromagneticLaser RadiationLasersMIC-1 gene productMIC1Macrophage Inhibitory Cytokine-1Malignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant neoplasm of prostateMalignant prostatic tumorMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMethodsModelingMonitorMorbidityMorbidity - disease rateNAG-1 proteinNAG1NSAID activated gene-1 productNSAID-Activated Protein 1NSAID-Regulated Protein 1National Detection Research NetworkNonsteroidal Anti-Inflammatory Drug-Activated Protein 1Numerical valuePLABPLAB ProteinPTGF-BetaPTK ReceptorsPatient TriagePatientsPerformancePlacental Bone Morphogenic ProteinPlacental TGF-BetaPopulation SurveillancePost-Translational Modification Protein/Amino Acid BiochemistryPost-Translational ModificationsPost-Translational Protein ModificationPost-Translational Protein ProcessingPosttranslational ModificationsPosttranslational Protein ProcessingPredictive ValuePrincipal InvestigatorProceduresProstateProstate CAProstate CA therapyProstate CancerProstate Cancer therapyProstate Differentiation FactorProstate GlandProstate malignancyProstatic GlandProtein GlycosylationProtein ModificationProteinsProteomicsPublic Health SurveillanceReactionReceptor Protein-Tyrosine KinasesReceptor Tyrosine Kinase GeneResearch ResourcesResearch SpecimenResourcesRiskSerumSpecificitySpecimenSurveillance ProgramSystematicsTEK Tyrosine KinaseTIE-2 ReceptorTIE-2 Receptor Tyrosine KinaseTIE-2-RTKTIE2 Tyrosine KinaseTarget PopulationsTechnologyTek ReceptorTie2 ReceptorTimeTissuesTranslatingTranslationsTransmembrane Receptor Protein Tyrosine KinaseTunica Interna Endothelial Cell KinaseTyrosine Kinase Linked ReceptorsTyrosine Kinase ReceptorsTyrosine-Protein Kinase Receptor TEKTyrosine-Protein Kinase Receptor TIE-2UniversitiesUrineValidationWorkactive followupanti-cancer therapyassay developmentbio-markersbiologic markerbiomarkerbiomarker arraybiomarker developmentbiomarker discoverybiomarker panelbiomarker validationcancer biomarkerscancer diagnosiscancer markerscancer therapycancer typecancer-directed therapycandidate biomarkercandidate markerclinical developmentclinical diagnosticsclinical interventionclinical significanceclinical testclinical therapyclinical validationclinically significantcomputational modelingcomputational modelscomputer based modelscomputerized modelingcostdevelopmentaldisease riskdisorder riskenrollexperiencefollow upfollow-upfollowed upfollowupglycoproteomicsgrowth differentiation factor 1growth differentiation factor 15high riskimprovedin-vitro diagnosticsindexingindustrial partnershipindustry partnerindustry partnershipinnovateinnovationinnovativeinterestlab developmentlaboratory developmentlaser capture microdissectionmarker panelmarker validationmedical diagnosticmenmortalitymulti-modalitymultidisciplinarymultimodalitynovelover-treatmentovertreatmentp140 TEKpredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerprogression riskprostate cancer cellprostate cancer riskprostate cancer treatmentprostate tumor cellresearch clinical testingsingle cell analysissyndecantechnology platformtechnology systemtissue biomarkerstranslationtrial regimentrial treatmentvalidationsverification and validation
Description preview
Active surveillance (AS) is the preferred management option for low risk prostate cancer (PCa) patients who
would benefit from conservative treatment. However, due to the lack of reliable methods in the initial clinical
evaluation to identify true low-risk PCa patients for AS enrollment and during AS monitoring to detect a rising
risk of…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click